BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 2022;21:184. [PMID: 36163047 DOI: 10.1186/s12943-022-01657-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Kim J, Lee H, Choi H, Min H. Discovery of Myeloid-Derived Suppressor Cell-Specific Metabolism by Metabolomic and Lipidomic Profiling. Metabolites 2023;13:477. [DOI: 10.3390/metabo13040477] [Reference Citation Analysis]
2 Su Y, Jin G, Zhou H, Yang Z, Wang L, Mei Z, Jin Q, Lv S, Chen X. Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy. Medical Review 2023;0. [DOI: 10.1515/mr-2022-0048] [Reference Citation Analysis]
3 Wang W, Chen H, Yin S, Yang Z, Zhang F. Targeting adipocyte-immune cell crosstalk to control breast cancer progression. J Cancer Res Clin Oncol 2023. [PMID: 36914785 DOI: 10.1007/s00432-023-04685-3] [Reference Citation Analysis]
4 Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G. Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines 2023;11:636. [DOI: 10.3390/vaccines11030636] [Reference Citation Analysis]
5 Starska-kowarska K. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers 2023;15:1642. [DOI: 10.3390/cancers15061642] [Reference Citation Analysis]
6 Li Q, Mei A, Qian H, Min X, Yang H, Zhong J, Li C, Xu H, Chen J. The role of myeloid-derived immunosuppressive cells in cardiovascular disease. Int Immunopharmacol 2023;117:109955. [PMID: 36878043 DOI: 10.1016/j.intimp.2023.109955] [Reference Citation Analysis]
7 Wen J, Xuan B, Gao Y, Liu Y, Wang L, He L, Meng X, Zhou T, Tao Y, Guo K, Wang Y. Lnc-17Rik promotes the immunosuppressive function of Myeloid-Derived suppressive cells in esophageal cancer. Cell Immunol 2023;385:104676. [PMID: 36780770 DOI: 10.1016/j.cellimm.2023.104676] [Reference Citation Analysis]
8 Huang R, Wang Z, Hong J, Wu J, Huang O, He J, Chen W, Li Y, Chen X, Shen K. Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy.. [DOI: 10.21203/rs.3.rs-2419604/v1] [Reference Citation Analysis]
9 Jing Y, Zeng H, Cheng R, Tian P, Li Y. [Advances of Immunotherapy Resistance and Coping Strategies 
in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2023;26:66-77. [PMID: 36792083 DOI: 10.3779/j.issn.1009-3419.2023.102.03] [Reference Citation Analysis]
10 Lu J, Liang T, Li P, Yin Q. Regulatory effects of IRF4 on immune cells in the tumor microenvironment. Front Immunol 2023;14:1086803. [PMID: 36814912 DOI: 10.3389/fimmu.2023.1086803] [Reference Citation Analysis]
11 Kast RE. High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth-Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen. Cancers (Basel) 2022;14:4965. [PMID: 36230888 DOI: 10.3390/cancers14194965] [Reference Citation Analysis]
12 Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol 2022;15:142. [PMID: 36209176 DOI: 10.1186/s13045-022-01363-8] [Reference Citation Analysis]